This is the second article in a three-part series on women's health issues. The series will discuss osteoporosis, cardiovascular disease, and the Bethesda classification system for Papanicolaou smears. On completion of this series, the reader will be able to describe laboratory findings associated with osteoporosis, list factors contributing to cardiovascular disease in women, and explain aspects of the Bethesda system for reporting Pap smears. Cardiovascular disease is an important cause of morbidity and mortality in women. Each year in the United States, cardiovascular disease results in the death of approximately 500,000 women and hospitalization of approximately 2.5 million more women. Considerable advances in the understanding of cardiovascular disease, including in women, have been made during this century. A better understanding of cardiovascular disease in women, the effect of estrogen on the cardiovascular system in women, and the role of hormone therapy in cardiovascular health and disease in women should improve health care in women overall.
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Cardiovascular Disease in Women
Certain health problems, such as breast cancer, rheumatoid arthritis, and osteoporosis, affect women more frequently than men. However, cardiovascular disease is the most common cause of death in women and men. Although many features of cardiovascular disease are similar in men and women, during the past 30 years, a number of studies have demonstrated significant gender differences (Table 1) . For example, women, on average, have less heart disease than men at any level of every major risk factor except diabetes. As a result, on average, women live longer than men.
Cardiovascular disease may be classified as coronary artery disease, valvular heart disease, congestive heart failure, sudden cardiac death, stroke, or peripheral vascular disease. Of these types, the largest differential for survival between men and women is in coronary artery disease. Although men are 2.5 to 4.5 times more likely to die of coronary artery disease than are women, it is an important health problem in women. In fact, coronary artery disease is the most common cause of death among women in the United States. Once women have coronary artery disease, the prognosis, whether the disease is treated medically or surgically, is worse for women than for men. The rate of early death after myocardial infarction is higher for women than for men. Similarly, the in-hospital mortality rate for coronary angioplasty and the mortality rate for coronary artery bypass surgery are higher in women than in men. This poorer prognosis is believed due, in part, to the smaller size of women and the associated smaller size of their blood vessels and, in part, to psychosocial factors.
Numerous psychosocial factors have an important effect on the recognition and management of cardiovascular disease in women. Women usually are older than men when they seek medical care for cardiovascular diseases. Even though women usually experience angina as their first symptom, this symptom is less often recognized as pain coming from the heart. Consequently, coronary artery disease is often more advanced when first diagnosed In-hospital death rate higher in women. In addition, because women are generally older when they develop coronary artery disease, they are frequently more socially isolated than men who have coronary artery disease. Older women who have outlived their male partners often experience more economic deprivation as well. For an older woman, living alone increases the risk of recurrent cardiac events.
In the past, women have undergone evaluation for cardiovascular disease, especially chest pain, much less frequently than have men. Women undergo fewer invasive diagnostic procedures than men despite more disabling symptoms. As a result, the treatment of coronary artery disease usually has been delayed in women. Women are less likely than men to undergo coronary angioplasty, coronary bypass surgery, and valve replacement. Management of myocardial ischemia, infarction, and valvular heart disease in women, however, should be the same as in men, and diagnostic tests generally should be applied in the same fashion as for men. For example, treadmill exercise tests, exercise testing with thallium, and stress echocardiography should be used for the same indications in women as in men. After coronary artery disease has been diagnosed in a woman, careful consideration should be given to the risks and benefits of coronary angioplasty, coronary artery bypass surgery, or valve replacement. When appropriate, these therapies, as well as medical therapy, should be applied according to the same guidelines as for men.
Aortic valve stenosis is an important cause of morbidity and mortality in elderly women. Coronary artery disease adds considerably to the surgical mortality of aortic valve replacement. Rheumatic heart disease and its management in women also are complicated by the presence of coronary artery disease. Women with congestive heart failure are frequently older than men with congestive heart failure. Current evidence suggests these problems respond favorably to therapy.
Little is known about sudden death due to cardiovascular causes in women. However, women with coronary artery disease who survive cardiac arrest may be more likely than men to have a treatable form of ventricular tachycardia.
Another important cause of morbidity and mortality in women is stroke. The prevalence of essential hypertension is higher in men than in women, but this difference decreases with age. Hypertension is a risk factor for stroke and myocardial infarction in older women. Diabetes has a greater contribution to die risk of stroke in women than in men. Women have less severe carotid artery disease than do men, but the rate of restenosis after carotid endarterectomy is greater in women than in men. Peripheral vascular disease is much more common in men than in women. However, aortic aneurysm is discovered later and is more likely to have ruptured in women than in men.
The Effect of Estrogen on the Cardiovascular System in Women
Several studies have demonstrated that the sex hormones, estrogen and progesterone, have important effects on the female cardiovascular system during the reproductive years. Estrogen and progesterone increase blood volume and RBC mass, and estrogen increases vascular capacitance and vascular compliance (the size and capacity of the cardiovascular system). Progesterone, but not estrogen, increases left ventricular mass; estrogen increases left ventricular chamber size. In addition, menotropinsinduced increase in estrogen has been associated with increased left ventricular size in infertile women undergoing ovulation induction. Through these actions, estrogen and progesterone are believed to have an important role in the cardiovascular adaptations to pregnancy. Less is known about the effects of the sex hormones, estrogen and progesterone, on the cardiovascular system of older women. Postmenopausal women have a substantial increase in the incidence of myocardial infarction, and there is a decrease in the risk of coronary artery disease in postmenopausal women receiving estrogen therapy. Although important, estrogen's favorable effect on the lipid profile alone does not account for all of the beneficial cardiovascular effects of estrogen therapy. Other mechanisms may contribute to this reduction in risk of coronary heart disease.
With age, the aorta and its branches become less compliant (or stiffen). After menopause, the process of decreasing compliance may progress more rapidly. Acceleration of atherosclerosis and decreased aortic compliance after menopause may contribute to the development of hypertension. Furthermore, the reduction in aortic compliance coupled with increasing systemic vascular resistance with advancing age increases the systolic load of the heart. Estrogen has been shown to increase the compliance of the aorta in premenopausal women and to increase the size of the aorta in postmenopausal women. Considered together, these observations are consistent with the notion that estrogen facilitates maintenance of cardiovascular health in postmenopausal women.
Epidemiologic studies have shown that women lose their "protection" against coronary artery disease after menopause. The Nurses' Health Study found that women who experienced early menopause due to bilateral oophorectomy had greater risk of coronary artery disease compared with premenopausal women of the same age. After 10 years of follow-up, postmenopausal women receiving hormone therapy had a reduced risk of coronary disease. The cardioprotection in premenopausal women has generally been attributed to endogenous estrogen. Similarly, several large population-based studies have shown that estrogen therapy decreases the risk of coronary artery disease in postmenopausal women. The mechanisms for estrogen's cardiovascular protective effect are not completely understood. Supplemental estrogen has been shown to increase high-density lipoprotein cholesterol levels and decrease low-density lipoprotein cholesterol and Lp(a) lipoprotein levels. Estrogen also has inherent antioxidant effects and favorably influences endothelial function, vascular compliance, and insulin sensitivity.
The Role of Hormone Therapy in Cardiovascular Health and Disease in Women
Recommendations about the use of estrogen replacement in postmenopausal women have varied. Experts in Canada and the United States have recommended against routine estrogen replacement in postmenopausal women but have suggested that women at high risk of osteoporosis, fracture, and coronary artery disease receive estrogen therapy. A study group of the American College of Physicians has evaluated estrogen replacement by estimating the net effect on longevity of all risks and benefits. The group concluded that estrogen reduces the risk of fracture and coronary artery disease and increases the risk of endometrial cancer, and it may increase the risk of breast cancer. The Reduces the risk of fracture related to osteoporosis therapy for women at high risk of osteoporosis, """ ; i ""*". ; ; , , ,. Concomitant use of progestins eliminates the supplemental fracture, or coronary artery disease.
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